spacer
home > ict > winter 2009 > alert to alzheimer's
PUBLICATIONS
International Clinical Trials

Alert to Alzheimer's

 

New treatments for Alzheimer’s disease (AD) have been the focus of intensive research efforts over the past few years with the growing appreciation of the healthcare impact that this disease is having on an ageing society. The increase in knowledge of the pathogenesis of this disease has been the basis for many new approaches to treating it, but progression of drug candidates in early clinical trials remains a challenge. Alzheimer’s disease is a presumptive diagnosis, made after the exclusion of other possible sources of dementia. Often, neurodegeneration is slow in the early stages of the disease where the best hope exists to stop or potentially reverse the long-term effects. This results in early clinical studies of long duration in order to provide a meaningful early signal of efficacy. No biomarkers exist yet to replace the complex battery of patient assessment tools that are currently accepted as efficacy endpoints. Managing inter- and intra-subject variability in efficacy measures is a key element in study design and management. Older patients have other health conditions that require therapy, so the design of early clinical studies is fraught with questions of which patients taking what concomitant therapies should be allowed on study. Effective future therapy for Alzheimer’s disease will likely be a combination of drugs that work together to yield a reasonable outcome. Clinical trial designs for combination therapies will be lengthy, large and complex.

THERAPEUTIC APPROACHES FOR ALZHEIMER’S DISEASE

Several very recent reviews have been written on the various therapeutic approaches to AD (1-4). In addition to the products currently available that amplify neurotransmission along key cholinergic and serotoninergic pathways (cholinesterase inhibitors and the NMDA glutamate receptor antagonist, memantine), there are compounds in clinical trials that block the formation of amyloid beta (gammasecretase inhibitors), increase the clearance of amyloid beta (antibodies and vaccines targeted to these proteins) and affect the formation of tau proteins and neurofibril tangles – all histopathological hallmarks of AD. An emerging class of drugs appears to protect neurons from the toxic effects of amyloid-beta and cellular oxidative stress. Interest in agents that enhance cerebral blood flow or improve mitochondrial energy efficiency is built on the knowledge that oxygenation and energy balance in the brain are important in maintaining optimal neuronal function. Neurotrophic stimulation by drugs or gene therapy results in enhanced growth of neurofibrils, and holds the promise of stimulating the development of new neural pathways and perhaps improving cognitive functioning. In addition, the clinical research field is crowded with studies evaluating the potential effects of drugs that reduce inflammation or enhance cellular glucose uptake, as well as analogues of vitamins E and natural dietary supplements such as ginkgo biloba.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

As Vice President of Drug Development at MDS Pharma Services, Fred Pritchard, PhD, leads a team of drug development experts who work actively with clients to bring their drug products from the pharmacology lab into clinical testing in patients. Over the past four years his team has shepherded 12 drugs into the clinic, several of these driven by key biomarkers. Fred brings 27 years of drug development experience to his work, including pre-registration work on five currently marketed pharmaceuticals. He is the author of over 100 scientific publications and abstracts, and is an invited speaker on managing risk during drug development.

spacer
Fred Pritchard
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Optimizing pharmaceutical processes

An increase in requirements from regulatory agencies around the world, combined with a growing demand for drugs in prefilled injections systems – a trend that industry experts have projected will continue – has led pharmaceutical and biotech supply chains to gain in significance. Well established and optimized processes are crucial for offering uninterrupted market supply. To satisfy its customers a CDMO must foster flexibility, efficiency and safety throughout the entire supply chain. The most important goal for all parties involved in the bio-pharma business is maximization of product quality where even small decisions can make a big difference. Future-oriented pharma processes can add value to any compound.
More info >>

White Papers

Clinical Trial-Specific Travel Programs as a Patient Retention Tool

For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement